Skip Navigation

Publicaciones covid-9

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Samantha Gillenwater, Franck Rahaghi, Anas Hadeh
?  Evaluación: (not yet rated)
Resumen

We would like to direct attention to the enrollment criteria in the trial described in the article by Beigel et al. (published online on May 22 at NEJM.org).1 In patients with Covid-19–related respiratory disease, these criteria resulted in the use of remdesivir well into the illness. The median time from symptom onset to randomization was 9 days.

Procedencia del autor
Texto completo
Tipo de documento
Especialidad(es)
Publicado en el sitio 2020-07-15 18:07:14

Comentarios

(aún no hay comentarios disponibles para este recurso)